Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
New clinical trials report from PA Consulting suggests biopharma companies are not keeping pace with changing public attitudes to sharing their medical data | ||
By: PR Newswire Association LLC. - 29 Feb 2024 | Back to overview list |
|
65% of Americans are willing to share their data across multiple studies if it could help accelerate the development of new treatments NEW YORK, Feb. 29, 2024 /PRNewswire/ -- US patients are willing to share their health data across clinical trials studies, offering the potential for global biopharma organizations to radically increase the pace of R&D, according to new data from PA Consulting (PA), the company that's bringing ingenuity to life. Six in 10 (64%) respondents said that they would be comfortable sharing their health data with researchers, and 65% said that they would be willing to share their data across multiple studies if it could help accelerate the development of new treatments or cures, according to PA's latest "Taking the Pulse" survey. Significant advances in technology are enabling secure data sharing and new analysis approaches. But global biopharma leaders need to do more to help US consumers benefit from the trust and commitment they make when participating in clinical research. Additionally, half of respondents (51%) said the pace of medical advancements in the US is too slow, while 47% said the US should invest more in emerging technologies like artificial intelligence for medical diagnosis and treatment. Having clean, at scale data to work with will lead to better and faster research results and will support the development and approval of new therapies that are critically needed to save lives and lower the cost of development for new drugs. Additional findings from the survey show that:
Charlie Paterson, clinical development expert at PA Consulting, said: "We are seeing a great appetite from the public to participate in clinical research, and to amplify the impact of their participation by their willingness to share data across studies. However leading life sciences companies must ensure that the technologies they deploy are supporting their ability to safely manage the data they are being trusted to use. Engaging the public will be crucial, so Clinical Development Leaders must accelerate efforts to digitize and to harness AI to organize their data and to demonstrate impact while consumer sentiment is positive. Organizations need to be creative with patient facing brands to reach potential trial participants, and should consider outsourcing trials to organizations, such as leading Contract Research Organizations, that have invested in data, design and technology to improve recruitment, participation and adherence. If we can increase trust in clinical trials, we expect to see much more diversity and inclusion in trials and therefore, a broader, more representative population to study and learn from." Methodology About PA. View original content to download multimedia:https://www.prnewswire.com/news-releases/new-clinical-trials-report-from-pa-consulting-suggests-biopharma-companies-are-not-keeping-pace-with-changing-public-attitudes-to-sharing-their-medical-data-302076022.html SOURCE PA Consulting Group - US |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |